首页|Bevacizumab as a second-or later-line of treatment for metastatic colorectal cancer
Bevacizumab as a second-or later-line of treatment for metastatic colorectal cancer
扫码查看
点击上方二维码区域，可以放大扫码查看
原文链接
NETL
NSTL
万方数据
AIM:To determine the efficacy of bevacizumab in patients with metastatic colorectal cancer (MCRC) who have failed prior chemotherapy without bevacizumab.METHODS:Between March 2002 and June 2010,40 patients in South Korea with MCRC who were treated with bevacizumab plus chemotherapy as a second or later-line treatment were analyzed retrospectively for their overall response rate (ORR),overall survival (OS),and progression-free survival (PFS).The tumor responses were assessed using the Response Evaluation Criteria in Solid Tumors guidelines.RESULTS:All of the patients had progressed under prior chemotherapy without bevacizumab.Three patients (7.5％) exhibited an ORR,twenty one patients (52.5％)exhibited stable disease (SD),and fifteen patients (37.5％) exhibited disease progression.The median duration of the OS and PFS were 14.0 mo and 6.13 mo respectively.The median OSs were 16.60,14.07 and 13.00 mo for second-line,third-line and fourth-or later-line treatments,respectively.The median PFSs were 7.23,7.30 and 3.87 mo for the second-line,third-line and fourth-or later-line treatments,respectively.CONCLUSION:In patients with MCRC,bevacizumab combined chemotherapy may be beneficial during second-or later-line treatment.
NETL
NSTL
万方数据
